New cytotoxic agents: A review of the literature

Katsuyuki Hotta, Hiroshi Ueoka

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The goal of treatment for patients with advanced cancer is to prolong survival, control symptoms, and reduce disease-related complications. Despite the introduction of many cytotoxic agents during the past decade, only modest improvement in survival has been achieved. In order to urgently improve these situations, new cytotoxic agents as well as molecular-targeted agents are now under investigation. In this article, we reviewed the latest information regarding antitumor activity, toxicity, pharmacokinetics, and clinical application of the new cytotoxic agents.

Original languageEnglish
Pages (from-to)45-65
Number of pages21
JournalCritical Reviews in Oncology/Hematology
Volume55
Issue number1
DOIs
Publication statusPublished - Jul 2005

Fingerprint

Cytotoxins
Survival
Pharmacokinetics
Neoplasms
Therapeutics

Keywords

  • Cancer chemotherapy
  • Cytotoxic
  • New drug

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

New cytotoxic agents : A review of the literature. / Hotta, Katsuyuki; Ueoka, Hiroshi.

In: Critical Reviews in Oncology/Hematology, Vol. 55, No. 1, 07.2005, p. 45-65.

Research output: Contribution to journalArticle

@article{3c053a9d58b140f9995c32f09eb8f714,
title = "New cytotoxic agents: A review of the literature",
abstract = "The goal of treatment for patients with advanced cancer is to prolong survival, control symptoms, and reduce disease-related complications. Despite the introduction of many cytotoxic agents during the past decade, only modest improvement in survival has been achieved. In order to urgently improve these situations, new cytotoxic agents as well as molecular-targeted agents are now under investigation. In this article, we reviewed the latest information regarding antitumor activity, toxicity, pharmacokinetics, and clinical application of the new cytotoxic agents.",
keywords = "Cancer chemotherapy, Cytotoxic, New drug",
author = "Katsuyuki Hotta and Hiroshi Ueoka",
year = "2005",
month = "7",
doi = "10.1016/j.critrevonc.2005.01.006",
language = "English",
volume = "55",
pages = "45--65",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - New cytotoxic agents

T2 - A review of the literature

AU - Hotta, Katsuyuki

AU - Ueoka, Hiroshi

PY - 2005/7

Y1 - 2005/7

N2 - The goal of treatment for patients with advanced cancer is to prolong survival, control symptoms, and reduce disease-related complications. Despite the introduction of many cytotoxic agents during the past decade, only modest improvement in survival has been achieved. In order to urgently improve these situations, new cytotoxic agents as well as molecular-targeted agents are now under investigation. In this article, we reviewed the latest information regarding antitumor activity, toxicity, pharmacokinetics, and clinical application of the new cytotoxic agents.

AB - The goal of treatment for patients with advanced cancer is to prolong survival, control symptoms, and reduce disease-related complications. Despite the introduction of many cytotoxic agents during the past decade, only modest improvement in survival has been achieved. In order to urgently improve these situations, new cytotoxic agents as well as molecular-targeted agents are now under investigation. In this article, we reviewed the latest information regarding antitumor activity, toxicity, pharmacokinetics, and clinical application of the new cytotoxic agents.

KW - Cancer chemotherapy

KW - Cytotoxic

KW - New drug

UR - http://www.scopus.com/inward/record.url?scp=20344403500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20344403500&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2005.01.006

DO - 10.1016/j.critrevonc.2005.01.006

M3 - Article

C2 - 15927843

AN - SCOPUS:20344403500

VL - 55

SP - 45

EP - 65

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -